You are here

Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44GM149095-01A1
Agency Tracking Number: R44GM149095
Amount: $1,272,176.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA22-176
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-06-01
Award End Date (Contract End Date): 2025-05-31
Small Business Information
Champaign, IL 61820-7460
United States
DUNS: 079414131
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 (949) 246-3113
Business Contact
Phone: (949) 246-3113
Research Institution

Principal Investigator/Program Director (Last, first, middle): Reddy, Jr., Bobby
Project Summary:
Sepsis is an incompletely understood clinical syndrome characterized by a dysregulated host response to
infection. In partnership with 8 U.S. hospitals, Prenosis amassed one of the world’s largest datasets and biobanks
that combines biomarker and clinical data for patients suspected of infection, housing over 70,000 plasma or
serum samples from over 14,000 patients. We also curated a dataset of dense time-series data from each
patient’s Electronic Medical Record (EMR), including demographics, vitals, lab results, interventions, outcomes,
and many other parameters. To commercialize insights from these data, Prenosis built ImmunixTM, an FHR/HL7
compatible software platform for clinical deployment of diagnostics and clinical decision support tools.
Under a previously awarded NIGMS grant (1R44GM139529), Prenosis built a testing pipeline to measure 40
critical protein biomarkers from biobanked samples. To date, we measured these biomarkers on only the initial
sample per patient for 6,000 patients and combined these data with EMR clinical parameters to construct 8
endotypes of sepsis. The identification and classification of endotypes—groupings of patients with similar
biologic and clinical features—is increasingly becoming recognized as a valuable methodologic approach to
assessing patients with sepsis. To complete work for the existing grant, Prenosis will measure the baseline
sample for additional patients to total about 10,000 patients to refine and validate the endotypes.
In this project, Prenosis proposes to add a critical new dimension to the data by assaying and analyzing
longitudinal, time-series biomarker data. We will leverage our pipeline to measure the 40 core biomarkers from
9,000 follow-up samples from ~3,400 patients that we have already collected and stored in the biobank. We
will assess the additional value of longitudinal time-series biomarker measurements and clinical data. Initial
feasibility data from over 1,000 measured samples demonstrates that longitudinal data provide additional
powerful new biologic and prognostic insights. Analytics built upon these data have the potential to improve
diagnostic and drug development products for sepsis and COVID. The overall hypothesis of this project is that
longitudinal biomarkers will add a valuable biologic and prognostic dimension to endotypes for sepsis; and these
longitudinal endotypes will better classify patients who may have a heterogeneous response to sepsis therapies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government